Entera Bio (ENTX) Non Operating Income (2021 - 2026)
Entera Bio (ENTX) recorded quarterly Non Operating Income of $34000.0 in Q1 2026, up 30.77% on a QoQ basis from $26000.0 in Q4 2025, and up 950.0% year-over-year from $3238.1 in Q1 2025.
Entera Bio (ENTX) Non Operating Income (2021 - 2026) Analysis & Trends
Entera Bio has disclosed Non Operating Income across 6 years of filings, most recently posting $34000.0 for Q1 2026.
- Quarterly Non Operating Income rose 950.0% year-over-year to $34000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $128000.0 (up 1322.22% YoY) and the FY2025 annual result came in at $90000.0, up 55.17% from the prior year.
- Non Operating Income grew to $34000.0 in Q1 2026, from $26000.0 in the prior quarter.
- Over five years, Non Operating Income peaked at $60000.0 in Q2 2022 and troughed at -$32000.0 in Q4 2023.
- A 5-year average of $18500.0 and a median of $21000.0 in 2023 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2023 — Non Operating Income plunged 146.15% — and 2026, when it jumped 950.0%.
- Tracing ENTX's Non Operating Income over 5 years: stood at -$13000.0 in 2022, then slumped by 146.15% to -$32000.0 in 2023, then surged by 78.12% to -$7000.0 in 2024, then soared by 471.43% to $26000.0 in 2025, then surged by 30.77% to $34000.0 in 2026.
- Business Quant data shows ENTX's Non Operating Income at $34000.0 in Q1 2026, $26000.0 in Q4 2025, and $56000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | 5.75 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | 444,000.00 |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 9.35 Mn |
| 10 | Entera Bio | 56.59 Mn | 52.45 Mn | - | 34,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 34,000.00 |
| Dec 31, 2025 | 26,000.00 |
| Sep 30, 2025 | 56,000.00 |
| Jun 30, 2025 | 12,000.00 |
| Mar 31, 2025 | -4,000.00 |
| Dec 31, 2024 | -7,000.00 |
| Jun 30, 2024 | 20,000.00 |
| Mar 31, 2024 | 45,000.00 |
| Dec 31, 2023 | -32,000.00 |
| Sep 30, 2023 | 36,000.00 |
| Jun 30, 2023 | 5,000.00 |
| Mar 31, 2023 | 22,000.00 |
| Dec 31, 2022 | -13,000.00 |
| Sep 30, 2022 | -8,000.00 |
| Jun 30, 2022 | 60,000.00 |
| Mar 31, 2022 | 44,000.00 |
| Dec 31, 2021 | -27,000.00 |
| Sep 30, 2021 | -7,000.00 |
| Jun 30, 2021 | -24,000.00 |
| Mar 31, 2021 | 29,000.00 |